Companies: 10,795·Total market cap: $144.5T
Innate Pharma S.A.

Innate Pharma S.A.

IPHANASDAQHealthcare● Active
$1.76
+$0.05(+2.92%)
Market Cap$165269787
P/E Ratio
52W High$2.63
52W Low$1.17

Innate Pharma S.A. (IPHA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

ipha · stock forecast · 6 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 6 Wall Street analysts in the past 3 months

SellBuy

Buy

6 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
4
Hold
2
Sell
0
Strong Sell
0
Total: 6 · Buy rate: 66.7%

12-Month Price Target

High

$5.00

Consensus

$3.50

+97.7% upside

Low

$2.00

Median: $3.5 · Last Close: $1.77

The Innate Pharma S.A. (IPHA) analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month IPHA price target is $3.50, representing +97.7% upside from the current price of $1.77.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $4 (97.7%)

Consensus Target

$3.50

97.7% upside

High Target

$5

182.5%

Low Target

$2

13.0%

Current Price

$1.77

as of today

Based on analyst price targets, the IPHA stock price prediction for the next 12 months ranges from $2 to $5. The consensus IPHA price forecast of $3.50 implies 97.7% upside from the current price of $1.77.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$1.751.40%

1-day model range: $1.7–$1.79. Peak: $1.79 (-1.40%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$1-50.0%
2028$1-62.5%
2029$1-67.2%
2030$1-69.2%
2031-70.2%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

64%15%21%
9Buy
2Neutral
3Sell
RSI (14)31.8Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · IPHA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$1.77NEUTRAL
MA 10$1.77BUY
MA 20$1.81SELL
MA 50$1.59BUY
MA 100$1.61BUY
MA 200$1.78SELL
Current $IPHA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$1.77BUY
EMA 10$1.78SELL
EMA 20$1.76BUY
EMA 50$1.67BUY
EMA 100$1.66BUY
EMA 200$1.74BUY
Current $IPHA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-04-07
Maintains
BuyBuy
BTIG2025-10-29
Maintains
BuyBuy
HC Wainwright & Co.2025-10-29
Upgrade ↑
NeutralBuy
Leerink Partners2025-09-18
Downgrade ↓
OutperformMarket Perform
HC Wainwright & Co.2025-09-18
Downgrade ↓
BuyNeutral
HC Wainwright & Co.2025-04-24
Maintains
BuyBuy
HC Wainwright & Co.2025-03-28
Maintains
BuyBuy
HC Wainwright & Co.2025-02-06
Maintains
BuyBuy
HC Wainwright & Co.2025-01-17
Maintains
BuyBuy
HC Wainwright & Co.2024-12-09
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Innate Pharma S.A. (IPHA) stock. Of the recent 34 rating actions, 3 were upgrades and 3 were downgrades. 6 analysts currently cover IPHA.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

IPHA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$31M

↓ 24.1% YoY

Revenue Next Year

$64M

↑ 106.8% YoY

EPS This Year

$-0.25

EPS Next Year

$0.04

↓ 117.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast IPHA EPS of $-0.25 for the current fiscal year, based on estimates from 2 analysts. The IPHA revenue forecast is $31M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The IPHA stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IPHA price target is $3.50 (+97.7% upside), with an analyst consensus of Buy.

The IPHA short-term stock prediction for tomorrow is $1.75 (-1.40%). The IPHA stock price prediction for 2027 estimates an average of $1. The IPHA stock prediction for 2030 projects a range of $0–$1.

Innate Pharma S.A. trades on NASDAQ under the ticker IPHA. The IPHA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

IPHA forecast · 8 questions

According to 6 Wall Street analysts, the average 12-month IPHA price target is $3.50, with a high forecast of $5.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies +97.7% potential upside from the current price of $1.77.

IPHA price targetWhat is IPHA price targetIPHA analyst price targetIPHA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.